Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s share price gapped up prior to trading on Thursday . The stock had previously closed at $11.35, but opened at $12.18. Mesoblast shares last traded at $12.41, with a volume of 211,220 shares.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald raised Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $18.00.
Check Out Our Latest Report on Mesoblast
Mesoblast Stock Performance
The company has a 50 day simple moving average of $11.21 and a two-hundred day simple moving average of $13.68. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.63 and a current ratio of 0.96.
Institutional Investors Weigh In On Mesoblast
Large investors have recently made changes to their positions in the company. Barclays PLC bought a new stake in shares of Mesoblast in the 4th quarter valued at approximately $38,000. JPMorgan Chase & Co. acquired a new stake in Mesoblast in the 4th quarter worth approximately $50,000. BNP Paribas Financial Markets lifted its holdings in Mesoblast by 86,566.7% in the 4th quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares during the last quarter. Tower Research Capital LLC TRC acquired a new stake in Mesoblast in the 4th quarter worth approximately $88,000. Finally, Advisors Preferred LLC lifted its holdings in Mesoblast by 224.9% in the 1st quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock worth $54,000 after purchasing an additional 3,169 shares during the last quarter. Institutional investors own 1.43% of the company's stock.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
